Health and Science

Biotech and Pharmaceuticals

stocks

Pharmas Market with Mike Huckman

Drug Retail

health science|biotech and pha|stocks|pharmas market|drug retail

health science|biotech and pharmaceuticals|stocks|pharmas market|drug retail

CNBC's Meg Tirrell reports the latest of the EpiPen controversy, including confirmation of Mylan overcharging Medicaid. CNBC senior markets contributor Mike Santoli and "Fast Money" trader Steve Grasso weigh in.